1-5 of 5
Elizabeth Hexner, MDMS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Abdulraheem Yacoub, MD, John Mascarenhas, MD, Heidi Elizabeth Kosiorek, MS, Josef T. Prchal, MD, Dmitriy Berenzon, MD, Maria R. Baer, MD, Ellen K Ritchie, MD, Richard T Silver, MD, Craig M. Kessler, MD, Elliott F. Winton, MD, Maria Chiara Finazzi, MD, Alessandro Rambaldi, MD Prof, Alessandro M. Vannucchi, David S. Leibowitz, MD, Damiano Rondelli, MD, Murat O. Arcasoy, MD, Rosalind Catchatourian, MD, Joseph Vadakara, MBBS, Vittorio Rosti, MD, Elizabeth Hexner, MDMS, Marina Kremyanskaya, MD PhD, Alicia Orellana, MD MPH, Lonette Sandy, Joseph Tripodi, Vesna Najfeld, PhD, Mohamed E. Salama, MD, Rona Singer Weinberg, PhD, Raajit K. Rampal, MD PhD, Ruben A Mesa, MD, Judith D Goldberg, ScD, Amylou C. Dueck, PhD, Ronald Hoffman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 321.
https://doi.org/10.1182/blood.V130.Suppl_1.321.321
Published: 2017
Journal Articles

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

Katherine D Cummins, BMBS, Noelle Frey, MD, Anne Marie Nelson, Aliza Schmidt, MS, Selina Luger, MD FRCPC, Randi E. Isaacs, MD, Simon F Lacey, PhD BS, Elizabeth Hexner, MDMS, J. Joseph Melenhorst, PhD, Carl H June, MD, David L Porter, MD, Saar I Gill, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1359.
https://doi.org/10.1182/blood.V130.Suppl_1.1359.1359
Published: 2017
Journal Articles

Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Amylou C. Dueck, PhD, John Mascarenhas, MD, Heidi Elizabeth Kosiorek, MS, Abdulraheem Yacoub, MD, Josef T. Prchal, MD, Dmitriy Berenzon, MD, Maria R. Baer, MD, Ellen K Ritchie, MD, Richard T Silver, MD, Craig M. Kessler, MD, Elliott F. Winton, MD, Maria Chiara Finazzi, MD, Alessandro Rambaldi, MD Prof, Alessandro M. Vannucchi, David S. Leibowitz, MD, Damiano Rondelli, MD, Murat O. Arcasoy, MD, Rosalind Catchatourian, MD, Joseph Vadakara, MBBS, Vittorio Rosti, MD, Elizabeth Hexner, MDMS, Marina Kremyanskaya, MD PhD, Alicia Orellana, MD MPH, Lonette Sandy, Joseph Tripodi, Vesna Najfeld, PhD, Mohamed E. Salama, MD, Rona Singer Weinberg, PhD, Raajit K. Rampal, MD PhD, Ronald Hoffman, MD, Ruben A Mesa, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4206.
https://doi.org/10.1182/blood.V130.Suppl_1.4206.4206
Published: 2017
Journal Articles

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Shernan G. Holtan, MD, Todd E. DeFor, MS, Joseph Pidala, MD PhD, Nandita Khera, MD, Stephanie J. Lee, MD PhD, Alan Howard, PhD, Juan Wu, F Javier Bolanos-Meade, MD, Vincent T Ho, MD, Amin M. Alousi, MD, Yoshihiri Inamoto, MD, George Chen, MD, Mukta Arora, MD, Jeanne Palmer, MD, Mary E. Flowers, MD, Corey S. Cutler, MD MPH, Alexander Lukez, Sally Arai, MD, Aleksandr Lazaryan, MD PhD MPH, Laura F. Newell, MD, Madan Jagasia, MD MBBS, MS, Iskra Pusic, MD, Sebastian A. Mayer, MD, William A. Wood, MD MPH, Anne Renteria, MD, William J. Hogan, MBBCh, Elizabeth Hexner, MDMS, Francis A Ayuk, Ernst Holler, MD, Yvonne A Efebera, MD, Rangsima Reantragoon, Hien Duong, MD, Gregory Yanik, MD, James L Ferrara, John E Levine, MD, Bruce Blazar, MD, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Margaret L. MacMillan, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 72.
https://doi.org/10.1182/blood.V130.Suppl_1.72.72
Published: 2017
Journal Articles

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, MD, Albert Thomas Quiery, MD, Deepti Radia, MD, Mark W Drummond, MB ChB, PhD FRCPath, Jason Gotlib, MD, William A Robinson, MD PhD, Elizabeth Hexner, MDMS, Srdan Verstovsek, MD PhD, Hongliang Shi, Terri Alvarez-Diez, Oleg Schmidt-Kittler, Erica Evans, PhD, Mary Ellen Healy, Beni B. Wolf, MD PhD, Michael W. Deininger, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2.
https://doi.org/10.1182/blood.V130.Suppl_1.2.2
Published: 2017